Pharmacokinetics and Pharmacodynamics of Ravulizumab in Adults with Generalized Myasthenia Gravis: Results from the Phase 3 CHAMPION MG Study (P3-1.002)

To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of the long-acting terminal complement C5 inhibitor ravulizumab in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG).